Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Douglas Berthiaume and More


Waters said this week that Douglas Berthiaume plans to retire from his position as CEO of the company sometime in the next two years.

The company's board of directors has appointed a succession planning committee to lead the selection of a successor, and it plans to hire an executive search firm. Waters said it plans to consider candidates who are already with the company and external candidates as well.

Berthiaume was appointed president and CEO of Waters in 1994, when the business was split from Millipore, and he took on the role of chairman in 1996. During his tenure, Waters said, the company has seen a 500 percent increase in revenues and a 25-fold increase in its share price since its IPO in 1995.

Biotheranostics has added three new members to its senior management team, including Gail Sloan as CFO, Macey Johnson as VP of managed care and reimbursement, and Matt Sargent as Breast Cancer Index commercialization leader.

Sloan previously was assistant controller at Affymax Research Institute, where she helped lead the spinoff of Affymetrix, and she was CFO and VP of finance at La Jolla Pharmaceutical. Johnson formerly worked at Genomic Health, where he developed managed care messaging and strategy for molecular assays, and he worked at Genentech, where he helped launch Avastin, Herceptin, and Tarceva.

Sargent recently was VP of oncology sales for Caris Life Sciences, where he built and trained the oncology sales team, and he has held senior sales and marketing positions at Exiqon Diagnostics and MedTrust Online.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.